structurebas
antigen
design
strategi
next
gener
vaccin
philip
r
dormitz
vaccin
design
progress
empiric
toward
increasingli
ration
present
target
protect
immun
nevertheless
current
vaccin
antigen
essenti
nativ
macromolecul
pathogen
molecul
adapt
evad
induc
immun
high
resolut
structur
reveal
electrostat
surfac
recogn
neutral
antibodi
architectur
underli
surfac
therebi
identifi
substructur
must
left
intact
chang
optim
biochem
immunolog
perform
arm
detail
structur
inform
engin
optim
antigen
stabl
homogen
effici
produc
make
immun
practic
afford
understand
structur
basi
immunogen
immunodomin
allow
us
improv
vaccin
efficaci
broaden
rang
vaccineprevent
diseas
glossari
adjuv
substanc
ad
antigen
enhanc
modul
immun
respons
antigen
immun
host
affin
matur
process
b
cell
produc
antibodi
increas
affin
antigen
upon
repeat
prolong
stimul
antigen
first
rearrang
immunoglobulin
gene
activ
b
cell
undergo
somat
hypermut
alter
complementaritydetermin
region
encod
antibodi
second
b
cell
express
mutat
immunoglobulin
undergo
clonal
select
clonal
select
b
cell
bear
immunoglobulin
greater
affin
limit
suppli
antigen
prolifer
bear
immunoglobulin
lower
affin
affin
matur
requir
cell
help
analyt
ultracentrifug
techniqu
measur
hydrodynam
characterist
particl
distribut
particl
solut
measur
time
spin
rotor
allow
observ
particl
sediment
diffus
techniqu
provid
inform
size
shape
particl
includ
noncoval
associ
complex
equilibrium
differ
associ
state
molecul
circular
dichroism
spectroscopi
techniqu
measur
differenti
absorpt
leftor
righthand
circularli
polar
light
chiral
molecul
protein
solut
spectrum
differenti
absorpt
ellipt
light
function
wavelength
provid
inform
protein
secondari
structur
composit
circular
dichroism
spectroscopi
use
determin
thermal
stabil
protein
determin
temperatur
order
secondari
structur
lost
conjug
link
carbohydr
antigen
protein
carrier
protein
carrier
elicit
cell
help
gener
immun
respons
includ
antibodi
carbohydr
deuterium
exchang
mass
spectrometri
techniqu
allow
inform
protein
conform
obtain
mass
spectrometri
solvent
expos
backbon
amid
side
chain
hydrogen
exchang
deuterium
solut
lower
ph
temperatur
exchang
slow
chargetomass
ratio
protein
fragment
determin
mass
spectrometri
comparison
mass
nativ
deuterium
exchang
sampl
allow
determin
region
protein
expos
solvent
buri
deuterium
exchang
take
place
differenti
scan
calorimetri
techniqu
measur
absorpt
heat
solut
function
temperatur
solut
contain
macromolecul
variat
absorpt
heat
temperatur
rais
give
inform
unfold
macromolecul
domain
use
structur
biologist
part
protein
form
coher
fold
unit
structur
element
domain
intim
interact
part
domain
part
protein
outsid
domain
dynam
light
scatter
techniqu
allow
measur
diffus
coeffici
base
variat
amount
light
scatter
small
volum
suspend
particl
time
base
assumpt
shape
particl
diffus
coeffici
may
use
estim
size
distribut
particl
techniqu
often
use
measur
polydispers
amount
variat
particl
size
electron
cryomicroscopi
electron
microscop
techniqu
specimen
imag
embed
vitreou
glasslik
rather
crystallin
ice
comput
averag
refin
result
low
contrast
data
yield
imag
reconstruct
biolog
specimen
consider
higher
resolut
convent
electron
micrograph
specimen
embed
neg
stain
contain
heavi
atom
enhanc
contrast
favor
case
near
atom
resolut
reconstruct
achiev
epitop
part
antigen
recogn
antibodi
group
antibodi
cell
receptor
escap
mutat
mutat
gene
encod
microbi
antigen
allow
microb
escap
kill
neutral
typic
antibodi
posit
alter
amino
acid
residu
antigen
structur
allow
infer
select
neutral
antibodi
bind
antigen
germlin
antibodi
repertoir
organ
collect
antibodi
yet
alter
somat
hypermut
affin
matur
isotherm
titrat
calorimetri
techniqu
measur
absorpt
product
heat
solut
second
solut
mix
two
solut
contain
interact
molecul
result
thermodynam
inform
allow
conclus
affin
stoichiometri
enthalpi
interact
molecul
mass
spectrometri
techniqu
measur
masstocharg
ratio
particl
techniqu
high
accuraci
throughput
combin
protein
fragment
comput
analysi
greatli
expand
applic
mass
spectrometri
protein
biochemistri
techniqu
use
identifi
protein
present
mixtur
provid
detail
inform
protein
primari
structur
posttransl
modif
nuclear
magnet
reson
spectroscopi
techniqu
measur
properti
magnet
field
gener
proton
atom
nuclei
abil
nmr
distinguish
proton
molecul
differ
electron
environ
measur
respons
molecul
proton
appli
magnet
puls
detect
interact
magnet
field
gener
proton
close
allow
conclus
molecular
structur
dynam
opson
enhanc
usual
bound
antibodi
antigen
uptak
phagocyt
antigen
present
cell
size
exclus
chromatographi
techniqu
separ
particl
solut
basi
siev
bead
pore
rate
particl
pass
size
exclus
column
determin
combin
size
shape
affin
bead
surfac
plasmon
reson
techniqu
measur
bind
molecul
solut
molecul
immobil
planar
metal
substrat
typic
gold
bind
detect
chang
refract
index
immedi
adjac
metal
surfac
molecul
solut
bind
immobil
molecul
data
allow
determin
onrat
offrat
bind
constant
k
xray
crystallographi
techniqu
use
diffract
xray
molecul
pack
crystallin
array
provid
inform
molecular
structur
xray
crystallographi
produc
atom
resolut
structur
object
rang
size
simpl
compound
entir
virus
correspond
author
dormitz
pr
philipdormitz
novartiscom
vaccin
use
today
evolv
two
old
empir
methodolog
pioneer
edward
jenner
loui
pasteur
jenner
use
attenu
infecti
agent
vaccin
inocul
cowpox
protect
smallpox
late
centuri
pasteur
pioneer
immun
nonrepl
prepar
pathogen
pasteur
techniqu
succinctli
summar
isol
caus
agent
inactiv
inject
techniqu
form
basi
effect
vaccin
bacteria
anthrax
virus
rabi
although
vaccin
progress
consider
sinc
earli
complex
poorli
defin
prepar
pustul
content
heat
inactiv
bacilli
extract
infect
spinal
cord
principl
vaccin
design
remain
fundament
modern
vaccin
rabi
tickborn
enceph
still
contain
entir
inactiv
pathogen
other
vaccin
tetanu
diphtheria
human
papillomaviru
hepat
b
contain
isol
molecul
known
target
protect
immun
refin
modern
vaccin
glycoconjug
oligosaccharid
structur
specif
bacteri
pathogen
conjug
carrier
progress
refin
reduc
nonprotect
reactogen
vaccin
compon
increas
safeti
toler
immun
nevertheless
modern
vaccin
still
use
nativ
antigen
except
genet
engin
modif
polybas
cleavag
site
hemagglutinin
prepandem
influenza
vaccin
signific
antigen
engin
licens
vaccin
consist
denatur
detoxif
conjug
mixtur
adsorpt
adjuv
vaccin
antigen
gener
engin
use
modern
genet
techniqu
best
avail
structur
data
one
except
genet
detoxifi
pertussi
toxin
use
acellular
pertussi
vaccin
alon
combin
diphtheria
tetanu
antigen
sever
year
europ
modif
guid
structur
homolog
toxin
pseudomona
aeruginosa
diphtheria
corynephag
contrast
small
molecul
therapeut
agent
often
result
de
novo
synthesi
extens
structurebas
modif
natur
deriv
substanc
ration
optim
antigen
could
improv
properti
vaccin
compon
nativ
surfac
protein
pathogen
adapt
evad
induc
immun
certainli
adapt
stabli
store
effici
produc
safe
inocul
need
structur
vaccinolog
use
nativ
antigen
proven
remark
success
wide
rang
pathogen
agent
vaccin
need
pathogen
success
vaccin
share
certain
characterist
gener
agent
humor
immun
protect
surfac
antigen
vari
quickli
new
variant
incorpor
updat
vaccin
exampl
includ
diphtheria
polioviru
hepat
b
viru
undergon
signific
antigen
chang
mani
decad
pathogen
tradit
techniqu
success
also
share
certain
characterist
one
characterist
lack
highli
express
surfac
antigen
suitabl
use
vaccin
compon
complex
pathogen
har
genom
revers
vaccinolog
overcom
barrier
revers
vaccinolog
whole
genom
sequenc
bacteria
fungi
parasit
mine
discov
new
protect
determin
previous
known
target
natur
immun
recombin
express
molecul
overcom
low
natur
abund
mani
case
prevent
recognit
potenti
vaccin
antigen
increas
set
nativ
antigen
choos
techniqu
enabl
develop
new
gener
vaccin
techniqu
led
discoveri
new
protect
antigen
pneumococcu
group
b
streptococcu
revers
vaccinolog
vaccin
candid
staphylococcu
aureu
meningococcu
b
clinic
trial
vaccin
refractori
pathogen
requir
differ
solut
exampl
virus
encod
asyet
undiscov
protect
antigen
hiv
hepat
c
viru
vari
surfac
antigen
rapidli
extens
antibodi
elicit
envelop
glycoprotein
neutral
strain
close
relat
strain
immunogen
deriv
furthermor
immun
respons
determin
certain
viral
agent
respiratori
syncyti
viru
dengu
viru
actual
exacerb
diseas
protect
new
target
face
practic
challeng
well
impoverish
set
new
vaccin
urgent
need
cost
product
distribut
vaccin
major
barrier
use
even
develop
world
expens
less
issu
number
immun
child
receiv
becom
increasingli
burdensom
optim
vaccin
antigen
combin
tool
genet
engin
insight
provid
high
resolut
structur
analysi
may
allow
us
overcom
barrier
figur
one
import
goal
structur
vaccinolog
select
present
conserv
determin
complex
variabl
antigen
distinguish
structur
compon
elicit
protect
diseaseenhanc
immun
could
avoid
vaccinemedi
exacerb
diseas
use
high
resolut
structur
antigen
design
effici
produc
stabli
store
nativ
molecul
therebi
lower
cost
elimin
barrier
distribut
engin
antigen
amen
use
combin
vaccin
immun
regimen
simplifi
know
part
antigen
must
retain
preserv
basic
characterist
alter
vaccin
antigen
modifi
rapidli
respons
chang
epidemiolog
basi
structur
engin
antigen
immun
pathogen
reli
prime
immun
system
specif
compon
microb
review
trend
biotechnolog
vol
target
protect
immun
case
cell
mediat
immun
epitop
short
peptid
lack
defin
threedimension
structur
therefor
knowledg
three
dimension
structur
antigen
essenti
design
peptidebas
cell
vaccin
often
consid
therapeut
purpos
nevertheless
knowledg
structur
basi
peptid
present
major
histocompat
antigen
provid
insight
peptid
design
futur
increas
knowledg
structur
basi
antigen
process
may
incorpor
protein
antigen
design
allow
effici
elicit
cell
help
contrast
epitop
recogn
neutral
antibodi
threedimension
structur
electrostat
landscap
primari
mechan
action
vaccin
clinic
use
present
target
landscap
therebi
induc
clonal
expans
b
cell
express
antibodi
specif
bind
surfac
promot
affin
matur
antibodi
neutral
epitop
form
residu
discontinu
primari
amino
acid
sequenc
although
high
affin
antibodi
recogn
pathogen
neutral
determin
may
also
bind
isol
unstructur
peptid
immun
peptid
unlik
elicit
high
titer
neutral
antibodi
pathogen
reliabl
neutral
antibodi
may
trap
flexibl
peptid
conform
match
surfac
intact
protein
howev
upon
immun
peptid
b
cell
bear
immunoglobulin
recogn
one
mani
conform
peptid
stimul
expand
peptid
immun
mechan
select
activ
b
cell
bear
immunoglobulin
bind
flexibl
peptid
complet
fold
antigen
furthermor
flexibl
peptid
could
guid
affin
matur
antibodi
mani
altern
path
also
optim
bind
pathogen
surfac
reliabl
affin
matur
antibodi
effici
recogn
specif
surfac
requir
immunogen
stabli
present
surfac
rather
transient
writh
state
resembl
desir
target
epitop
electrostat
landscap
neutral
epitop
identifi
combin
antigen
structur
analys
techniqu
list
tabl
sequenc
analysi
viral
variant
escap
neutral
monoclon
antibodi
mab
identifi
residu
alter
prevent
antibodi
bind
escap
mutant
analysi
particularli
use
rna
virus
retrovirus
whose
errorpron
polymeras
lead
high
mutat
rate
effici
gener
variant
longer
neutral
antibodi
gener
antibodi
bind
site
also
delin
physic
method
antibodi
neutral
escap
mutat
found
locat
within
antibodi
bind
site
key
limit
escap
mutant
analysi
mutat
compat
viral
replic
identifi
limit
overcom
target
mutagenesi
recombin
viral
antigen
follow
directli
assay
antibodi
bind
howev
failur
antibodi
bind
antigen
undergon
target
mutagenesi
must
interpret
carefullymut
may
prevent
antibodi
bind
yield
misfold
domain
rather
fall
within
anti
trend
biotechnolog
vol
bodi
bind
site
screen
phage
display
librari
neutral
antibodi
bind
provid
effici
screen
mani
sequenc
howev
util
phage
display
limit
inabl
rel
short
peptid
display
librari
reproduc
conform
epitop
deuterium
exchang
mass
spectrometri
bacteri
express
antigen
high
solubl
nuclear
magnet
reson
spectroscopi
identifi
antibodi
bound
residu
intact
protein
high
resolut
imag
antigenantibodi
complex
precis
delin
epitop
boundari
provid
essenti
inform
antigen
engin
xray
crystallographi
provid
definit
data
exampl
includ
high
resolut
structur
antibodi
complex
rhinoviru
virion
influenza
viru
hemagglutinin
hiv
combin
electron
cryomicroscopi
molecular
model
provid
approxim
crystal
structur
complex
obtain
exampl
includ
imag
reconstruct
antibodi
complex
rhinoviru
rotaviru
virion
basic
conclus
studi
antibodi
epitop
larg
patch
antigen
bound
antibodi
typic
cover
even
limit
number
residu
make
major
contact
antigen
antibodi
addit
residu
usual
necessari
maintain
epitop
structur
residu
alter
could
steric
hinder
antibodi
bind
limit
inher
epitop
map
method
involv
monoclon
antibodi
mab
given
immun
screen
protocol
yield
subset
potenti
antibodi
neutral
epitop
may
miss
exampl
due
cumbersom
natur
neutral
assay
mab
often
screen
primarili
bind
recombin
protein
inhibit
microbi
bind
receptor
screen
systemat
bias
neutral
antibodi
recogn
epitop
found
assembl
virus
antibodi
block
infect
postbind
step
mani
viral
neutral
determin
function
membran
fusion
disrupt
devic
viral
matur
receptor
bind
cell
entri
may
undergo
extens
conform
chang
conserv
epitop
may
present
specif
transient
conform
therefor
optim
molecul
immunogen
requir
stabil
one
advantag
conform
exampl
hiv
bind
site
secondari
cellular
receptor
chemokin
receptor
conserv
surfac
provid
epitop
recogn
broadli
neutral
antibodi
howev
conserv
epitop
assembl
dispers
structur
element
bound
primari
receptor
thu
conserv
surfac
stabli
present
alreadi
bound
cell
viru
entri
second
exampl
parainfluenza
viru
f
glycoprotein
rearrang
radic
differ
structur
virus
fuse
cellular
membran
figur
neutral
escap
mutat
relat
respiratori
syncyti
viru
f
glycoprotein
map
structur
element
analog
also
like
rearrang
radic
entri
differ
conform
glycoprotein
like
elicit
antibodi
differ
specif
neutral
capac
protein
lock
desir
conform
engin
cystein
form
new
disulfid
bond
compat
one
conform
structur
data
guid
select
residu
mutat
cystein
exampl
prefus
conform
influenza
ha
stabil
tether
three
head
ha
trimer
togeth
engin
intersubunit
cross
link
similarli
prefus
state
measl
viru
f
glycoprotein
stabil
disulfid
crosslink
introduc
top
coiledcoil
base
head
adjac
subunit
effect
modif
immunogen
yet
determin
type
mutat
favor
prefer
conform
includ
reinforc
disrupt
hydrophob
core
hydrogen
bond
network
salt
bridg
demonstr
studi
paramyxoviru
f
glycoprotein
theori
engin
mutat
could
also
stabil
transient
protein
conform
fusion
protein
pass
transit
stabl
preand
postfus
conform
stabil
transient
intermedi
could
allow
induct
antibodi
conserv
epitop
expos
transient
nativ
molecul
elicit
protect
antibodi
effici
select
optim
protein
antigen
requir
comprehens
evalu
structur
featur
recombinantli
produc
protein
ideal
analyt
tool
appli
high
throughput
manner
mani
candid
structur
abbrevi
auc
analyt
ultracentrifug
cd
circular
dichroism
spectroscopi
cryoem
electron
cryomicroscopi
dl
dynam
light
scatter
dsc
differenti
scan
calorimetri
dxm
deuterium
exchang
mass
spectrometri
elisa
enzymelink
immunosorb
assay
ip
immunoprecipit
itc
isotherm
titrat
calorimetri
mab
monoclon
antibodi
ms
mass
spectrometri
nmr
nuclear
magnet
reson
spectroscopi
sec
size
exclus
chromatographi
spr
surfac
plasmon
reson
trend
biotechnolog
vol
link
structur
mechan
neutral
antigen
design
structur
neutral
epitop
link
mechan
neutral
antibodi
demonstr
rotaviru
outer
capsid
protein
rotaviru
infect
effici
elicit
neutral
antibodi
immun
recombin
cell
entri
must
shed
virion
process
term
uncoat
rotaviru
virion
uncoat
vitro
calcium
remov
chelat
uncoat
caus
dissoci
calciumdepend
trimer
neutral
antibodi
inactiv
rotaviru
bind
specif
trimer
virion
stabil
prevent
uncoat
even
presenc
calcium
chelat
therefor
trimer
engin
enhanc
stabil
could
effect
elicit
neutral
antibodi
nativ
dynam
equilibrium
monom
trimer
solut
case
high
resolut
structur
understand
neutral
mechan
could
guid
engin
optim
antigen
engin
antigen
suffici
simpli
know
surfac
avail
antibodi
bind
also
necessari
understand
underli
protein
architectur
form
surfac
exampl
understand
underli
hiv
architectur
guid
delet
variabl
loop
bia
repertoir
elicit
antibodi
away
conserv
part
molecul
understand
underli
architectur
also
allow
sensibl
dissect
macromolecul
carv
protein
joint
interdomain
boundari
isol
autonom
fold
structur
domain
suitabl
independ
recombin
express
case
picornaviru
capsid
neutral
epitop
requir
intim
cofold
coassembl
protein
isol
domain
appar
carv
protein
shell
compon
feasibl
extrud
picronaviru
protein
except
contrast
complex
neutral
determin
collect
selfcontain
subunit
express
separ
exampl
subunit
includ
receptor
bind
domain
sar
coronaviru
glycoprotein
head
bodi
domain
rotaviru
spike
protein
studi
rotaviru
figur
illustr
advantag
reduc
complex
flexibl
macromolecul
neutral
epitopecontain
compact
domain
rotaviru
misfold
express
bacteria
suscept
proteolysi
aggreg
storag
howev
known
neutral
epitop
present
two
compactli
fold
domain
one
correspond
head
domain
spike
express
effici
escherichia
coli
resist
proteas
digest
stabl
solut
year
similar
effici
produc
compact
stabl
neutral
domain
sever
pathogen
like
homogen
biochem
characterist
multidomain
assemblag
deriv
domain
could
optim
alter
surfaceexpos
hydrophob
residu
caus
aggreg
modifi
proteas
cleavag
site
compromis
protein
stabil
collect
optim
domain
could
form
raw
materi
combin
vaccin
tailor
particular
patient
popul
epidemiolog
circumst
understand
engin
immunogen
appear
tradeoff
immunogen
biochem
ideal
promot
effici
antigen
product
stabil
storag
exampl
compact
stabl
solubl
effici
express
neutral
epitopecontain
domain
rotaviru
spike
protein
less
effect
elicit
neutral
antibodi
intact
protein
proteas
sensit
prone
aggreg
compact
stabil
solubl
monodispers
isol
wellfold
domain
appear
compromis
effect
immunogen
inde
protein
misfold
associ
enhanc
immunogen
therefor
optim
vaccin
antigen
requir
understand
structur
basi
immunogen
well
biochem
ideal
multival
one
manipul
structur
characterist
appear
enhanc
immunogen
order
array
antigen
elicit
b
cell
activ
antibodi
class
switch
affin
matur
absenc
antigen
present
cell
cell
help
postfus
f
rearrang
coiledcoil
tip
fusion
peptid
extend
purpl
domain
helic
make
prefus
coiledcoil
separ
pack
new
extens
form
sixhelix
bundl
rearrang
bring
cellular
viral
membran
close
apposit
extens
alter
solvent
expos
surfac
f
red
indic
fusion
peptid
color
indic
structur
domain
draw
base
structur
present
studi
immun
respons
immun
vesicular
stomat
viru
g
glycoprotein
indic
repetit
rigidli
g
glycoprotein
array
immunogen
becom
anoth
exampl
although
isol
bodi
domain
rotaviru
poor
immunogen
elicit
high
titer
neutral
antibodi
link
stabli
trimer
form
unpublish
observ
greater
immunogen
multival
antigen
may
reflect
adapt
immun
system
recogn
repetit
structur
character
mani
microorgan
observ
suggest
mount
compactli
fold
domain
multival
display
platform
could
increas
immunogen
platform
could
includ
selfoligomer
protein
form
multival
particl
use
human
immun
human
papillomaviru
hepat
b
viru
surfac
antigen
strategi
enhanc
immunogen
antigen
includ
engin
linkag
strong
cell
epitop
exemplifi
glycoconjug
vaccin
linkag
protein
bear
cell
epitop
enhanc
immunogen
bacteri
carbohydr
antigen
link
antigen
b
cell
epitop
recogn
highli
preval
antibodi
anoth
approach
increas
immunogen
exampl
link
domain
tetanu
toxoid
preexist
immun
preval
result
widespread
immun
tetanu
increas
immunogen
probabl
promot
opson
howev
circumst
linkag
also
decreas
immunogen
possibl
due
cellmedi
suppress
mask
preexist
antibodi
enhanc
clearanc
immun
complex
human
produc
oligosaccharid
termin
agalactosid
common
glycan
protein
organ
sugar
recogn
foreign
antigen
approxim
human
serum
antibodi
repertoir
recogn
agalactosid
knockout
mous
model
mimic
aspect
human
immun
addit
agalactosid
antigen
dramat
increas
immunogen
like
promot
opson
preexist
antibodi
recogn
carbohydr
structur
ultim
increas
understand
nativ
immun
may
also
allow
engin
antigen
directli
potenti
immun
recognit
present
addit
engin
antigen
make
immunogen
overal
would
desir
manipul
rel
immunodomin
differ
epitop
given
antigen
vaccin
purpos
would
best
conserv
epitop
elicit
antibodi
effici
variabl
epitop
howev
nativ
protein
opposit
often
case
exampl
high
proport
mab
neutral
hiv
envelop
glycoprotein
recogn
variabl
loop
wherea
conserv
region
elicit
neutral
antibodi
less
effici
similarli
bactericid
antibodi
elicit
immun
group
b
meningococc
vaccin
produc
outer
membran
vesicl
primarili
recogn
singl
variabl
loop
por
protein
one
explan
immunodomin
would
attribut
phenomenon
limit
set
avail
germ
line
antibodi
fit
epitop
antigen
combin
site
germ
line
antibodi
would
dictat
rel
domin
case
individu
germlin
antibodi
repertoir
would
determin
epitop
would
respond
preferenti
theori
primari
immun
antigen
present
epitop
engin
bind
preval
germlin
antibodi
could
effici
promot
clonal
expans
subsequ
boost
antigen
present
epitop
engin
match
precis
conserv
surfac
pathogen
protect
determin
could
guid
affin
matur
antibodi
stimul
b
cell
clone
altern
gener
topolog
electrostat
characterist
epitop
may
predict
abil
figur
rotaviru
spike
protein
rearrang
made
discret
compactli
fold
domain
undergo
rearrang
membran
penetr
trimer
molecul
thought
progress
initi
state
three
subunit
flexibl
shown
prime
state
two
subunit
rigid
third
remain
flexibl
b
fold
back
state
grey
receptor
bind
head
green
red
antigen
domain
contain
known
neutral
epitop
red
patch
depict
hydrophob
apex
antigen
domain
thought
interact
host
membran
effect
entri
motion
altern
pack
flexibl
element
cyan
foot
stalk
domain
drive
rearrang
rigid
domain
produc
digizym
inc
origin
publish
trend
biotechnolog
vol
effici
stimul
b
cell
expans
characterist
certainli
disfavor
antibodi
bind
exampl
modifi
hiv
surfac
ad
glycosyl
site
mask
epitop
alter
surfac
gener
glycosyl
lead
toler
glycan
virus
replic
host
gener
recogn
self
like
explan
immunolog
silenc
heavili
glycosyl
face
hiv
role
glycosyl
evad
immun
previous
expos
immun
host
suggest
evolut
subtyp
influenza
hemagglutinin
sinc
strain
emerg
human
pathogen
sinc
number
glycan
progress
increas
particularli
membran
distal
part
fragment
neutral
antibodi
bind
analog
might
possibl
abrog
immunodomin
variabl
region
ad
mask
oligosaccharid
region
convers
determin
glycan
import
protein
fold
solubl
glycan
mask
epitop
essenti
structur
role
could
allow
elimin
mask
glycan
enhanc
present
conserv
neutral
epitop
applic
modern
drug
discoveri
approach
vaccin
develop
potenti
markedli
expand
abil
screen
select
high
qualiti
vaccin
antigen
high
throughput
robot
protein
modif
system
develop
optim
protein
crystal
system
introduc
seri
mutat
proteinencod
gene
express
purifi
mutant
protein
carri
basic
character
fulli
autom
extrem
effici
manner
technolog
could
also
use
optim
vaccin
antigen
major
challeng
set
high
throughput
vitro
screen
characterist
relev
immunogen
perform
vivo
ultim
characterist
interest
abil
elicit
protect
immun
amen
autom
screen
eventu
ex
vivo
system
evalu
immun
prime
capabl
predict
immunogen
vivo
may
develop
therebi
greatli
facilit
vaccin
antigen
discoveri
process
research
consortium
fund
unit
state
defens
advanc
research
project
agenc
current
work
toward
goal
artifici
immun
system
use
rapidli
screen
antigen
immunogen
avail
autom
screen
limit
desir
antigen
characterist
express
level
solubl
stabil
aggreg
state
proteas
resist
epitop
present
tabl
combin
suffici
effici
assay
desir
characterist
high
throughput
protein
modif
could
provid
practic
altern
structur
base
design
case
exampl
express
suffici
number
empir
truncat
assay
gene
product
solubl
centrifug
monodispers
light
scatter
antigen
solut
immunoassay
one
could
identifi
autonom
fold
antigen
domain
without
knowledg
underli
protein
conform
use
conformationspecif
mab
detect
molecul
advantag
conform
high
throughput
mutagenesi
express
immunoassay
could
also
yield
protein
variant
stabil
desir
conform
biophys
biochem
genet
engin
technolog
need
structur
vaccinolog
sophist
concept
simpl
first
studi
nativ
molecular
architectur
neutral
determin
use
knowledg
modifi
molecul
engin
immunogen
optim
design
inclus
protect
vaccin
success
structur
vaccinolog
requir
applic
high
throughput
method
gener
larg
number
antigen
structur
assay
predict
effect
immunogen
current
knowledg
alreadi
optim
protein
antigen
effici
product
conform
homogen
stabl
storag
howev
fulli
realiz
potenti
structur
base
design
vaccin
antigen
requir
longerterm
basic
research
structur
determin
immunodomin
immunogen
research
must
take
account
divers
antibodi
repertoir
gener
singl
individu
also
differ
genet
background
histori
antigen
exposur
new
techniqu
sort
igg
antibodi
secret
plasma
cell
rapidli
clone
human
monoclon
antibodi
specif
recent
immunogen
make
analys
feasibl
applic
structur
insight
vaccin
design
especi
import
new
vaccin
viral
pathogen
greater
number
protect
determin
bacteria
fungi
parasit
make
suitabl
revers
vaccinolog
approach
discov
protect
determin
favor
vaccin
antigen
characterist
limit
number
protect
determin
virus
necessit
optim
rel
small
set
macromolecul
antigen
optim
limit
subunit
vaccin
live
attenu
vector
viruslikeparticl
vaccin
could
also
incorpor
antigen
optim
base
structur
insight
match
ration
design
antigen
advanc
ration
design
adjuv
enabl
new
gener
vaccin
safe
broadli
protect
practic
afford
avail
today
